-
Johnson & Johnson's Robust Pipeline Supports Its Above-Average Valuation
Wednesday, October 19, 2016 - 12:07pm | 343Read More...While noting that the shares of Johnson & Johnson (NYSE: JNJ) trade at a premium to Argus' universe of pharmaceutical stocks, the firm said the valuation is justified, given its robust new drug pipeline, improving device business and expanding opportunities in its consumer businesses. 3Q Review...
-
Pfizer Receives FDA Approval For Cheaper Version Of Johnson & Johnson's Top Drug Remicade
Wednesday, April 6, 2016 - 10:45am | 327Read More...Pfizer Inc. (NYSE: PFE) announced after Tuesday's market close that the U.S. Food and Drug Administration approved INFLECTRA, the first and only biosimilar monoclonal antibody therapy, and only the second biosimilar to be approved in the US. INFLECTRA is a treatment indicated for reducing...
